Institute for Clinical Research Official Portal

Clinical Research Centre

Hospital Selayang
Selangor

WhoWe Are

The Clinical Research Centre Hospital Selayang (CRC HS) has been in operation since 26 September 2006 and is part of the Network of Clinical Research Centres under the Ministry of Health (MOH). Its core functions are to coordinate research done by health care providers at Hospital Selayang (HS) including clinical registries, and organize training related to research. Services provided include coordinating web application set up and reviewing research proposals submitted by doctors from HS, proposals for research to be done at HS from medical students and university students of other institutions.

OurTeam

NAME POSITION QUALIFICATION EMAIL
Dr. Mohamad Aziz Salowi Head, Public Health Opthalmologist Consultant
MBBS, Masters of Surgery (Ophthalmology)
aziz.salowi@moh.gov.my 
Suhailah Zulkipli Admin Assistant  Diploma in Human Resources suhailah@crc.moh.gov.my 
Dr. Tay Ju Fan
Medical Officer (Admin Manager) MD jufan@moh.gov.my 
Dr. Hajar Ahmad Rosdi Medical Officer MD  hajara@moh.gov.my
Lee Fei Yee Pharmacist BPharm, MSc lfyee@moh.gov.my 

 

InvestigatorsHighlight

Image

 

Head of CRC, Public Health Ophthalmologist, Clinical Consultant, and Head of Selayang Cataract Centre, Hospital Selayang

Email: aziz.salowi@moh.gov.my  

MBBS, MS (Ophthal), PHO (CSST) 

Areas of interest: Public Health and Eyecare Research, Epidemiology, Cataract and Prevention of Blindness.

Awards and achievements:

  • Excellent Service Award, Ministry of Health Malaysia in 2005, 2018, and 2011
  • Rotary Vocational Service Award, year 2012
  • Rotary Frank Davlyn Excellence Award, year 2020
  • Certification as WHO Rapid Assessment of Avoidable Blindness (RAAB) Trainer for Asia Pacific Region, September 2014
  • Asia Pacific Academy of Ophthalmology (APAO) Outstanding Service in Prevention of Blindness, year 2016
  • Asia Pacific Academy of Ophthalmology (APAO) Achievement Award, year 2024
  • eCUSUM officially launched as performance monitoring and as part of the nationwide National Eye Database performance monitoring system on 13th November 2008.
  • WHO released the report on KK-KKM on 17/10/23 - Bringing High Impact, Good Quality and Low-Cost Eye Care Closer to Home – a case study of Klinik Katarak Kementerian Kesihatan Malaysia – WHO Innovation Challenge 2021

Dr. Aziz chairs the National Eye Database (NED), co-chairs the Ministry of Health (MOH) Prevention of Blindness and Cataract Services Monitoring Committee and is the country coordinator for the Klinik Katarak KKM (KK-KKM) network. He currently leads the work on Cataract Surgical Performance Monitoring within the Western Pacific Region, working with the World Health Organization (WHO) and the International Agency for the Prevention of Blindness (IAPB). He has written numerous cataract database reports, published multiple papers in peer-reviewed journals and is a reviewer for several scientific journals internationally. He is an examiner for the country's specialist credentialing exit examinations. He heads the Eye Research Advocacy initiative for MOH, is a National Medical Research Ethics Committee member, and has been a Trainer and Principal Investigator for eight population surveys on blindness (using RAAB methodology) since 2013. 

Research Highlights

CUSUM: A Dynamic Tool for Monitoring Competency in Cataract Surgery Performance – Br J Ophthalmol 2010;94:445-449. 

This publication is part of a master's program thesis on performance monitoring in cataract surgery, entitled “CUSUM: A Dynamic Tool for Monitoring Competency in Cataract Surgery Performance”. It has been incorporated as a web function in the NED since 2007. The system monitored and evaluated cataract surgeries based on surgical data input in real time from individual surgeons regardless of where the surgery was performed. The system has been used to assess candidates for exits in gazettement, National Specialist Register (NSR) certification and entry for ophthalmology subspecialty programs. The current work on CUSUM is to develop a risk-adjusted model to control the factors/risks influencing the outcome of surgery, hence producing a more robust analysis of the surgeons’ performance. 

Recent Publications

Changing Trend of Cataract Blindness and Visual Outcomes after Cataract Surgery in Adults Aged 50 Years and Older: Findings from the National Eye Surveys in Malaysia.

Improvement in the Effective Cataract Surgical Coverage in Malaysia: Evidence of Impact from a Mobile Cataract Outreach Program

Project Highlights

Image
Image
Image
NMRR-22-02450-WQK A Prospective Observational Cohort Study To Evaluate The Clinical Performance Of Treatments For Over-Granulating Peritoneal Dialysis Catheter Exit Sites In An Asian Population (COPE).
NMRR-22-01760-WDP A Randomized Controlled Trial on TauroLockTM-U 25,000 Lock Versus Standard of Care in Peritoneal Dialysis-related Peritonitis.
RSCH-23-05698-3XY Behavior, Aspirations and Treatment needs of people living with hepatitis B
NMRR-22-02886-BW4 Clinical Impact Of Low-Density Lipoprotein Cholesterol Targets In Acute Myocardial Infarction: Bridging Between Guidelines And Practice
RSCH-23-04567-ZWJ Cohort Study on the Maternal and Neonatal Outcomes of Pregnant Women with Systemic Lupus Erythematosus (SLE)
NMRR-23-00299-3IT Predictors and Comparison of Pathological Myopia leading to Myopic Choroidal Neovascularization: a 10 year study in Hospital Selayang
NMRR-23-01331-JKQ Prospective Study in Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Patients treated with EP2 Receptor Agonist - Omidenepag Isopropyl (OMDI) in a tertiary center in Malaysia
NMRR-15-2181-28116 Safety/Efficacy Study of ABT-494 to Treat Moderately to Severely Active Ulcerative Colitis
NMRR-15-2466-25348 A Multicenter, Double-blind, Long Term Extension Study to Access the Safety and Efficacy of Fligotinib in Subjects with Rheumatoid Arthritis
NMRR-18-1591-42483 A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis
NMRR-15-1094-26875 A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison with Mycophenolate Mofetil and Corticosteroids in Subjects with Class III/Iv±V Lupus Nephritis
NMRR -19-61-45889 An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis ( GPP)
NMRR-20-2598-57373 The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
NMRR-21-1256-60314 A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease (CNTO1959PSA4002)
NMRR-21-1271-60302 A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease
NMRR-21-800-59029 A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
NMRR-21-772-59755 Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutde in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial [FGF21 study]
NMRR-22-00421-2PS An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/- V
NMRR-21-1918-61166 A Phase 3, Long-Term Extension Study to Evaluate the safety and efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis
NMRR-22-01733-HGU A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis 
NMRR-22-01348-XLC A Phase IIIb/IV, Multicenter, Open-label, Single-arm study to investigate the efficacy and safety of faricimab (RO6867461) in patients with polypoidal choroidal vasculopathy
NMRR-22-02592-LFW A phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis
RSCH-22-05309-KOC A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)
NMRR-23-01010-N0F Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
NMRR-23-01234-LQE A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis
NMRR-22-02573-SYE/S2 A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial spondyloarthritis who achieved remission
NMRR-23-01235-NO0 A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis
NMRR-23-01937-CT2 An open-label, multicenter, single-arm, post-marketing trial (in select countries) to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v. 
NMRR-23-02546-OLS A Phase 2A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NMRR-23-03025-C7C A Randomized, Multiregional, double-blind,double dummy, parellel group, placebo and Allupurinol- controlled, phase 3 study to Assess the efficacy and Safety of Tigulixostat in Gout patients with Hyperuricemia
NMRR-23-01354-3XS/S5 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants
NMRR-23-03025-C7C A Randomized, Multiregional, double-blind,double summy, parellel group, placebo and Allupurinol- controlled, phase 3 study to Assess the efficacy and Safety of Tigulixostat in Gout patients with Hyperuricemia
NMRR-23-02547-EHN A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) Infection
NMRR-23-02339-9YB A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients

List of Publications associated with CRC HS

  1. Changing Trend of Cataract Blindness and Visual Outcomes after Cataract Surgery in Adults Aged 50 Years and Older: Findings from the National Eye Surveys in Malaysia
    •   Mohamad Aziz Salowi, Nyi Nyi Naing, Norasyikin Mustafa, Wan Radziah Wan Nawang, Siti Nurhuda Sharudin, Nor Fariza Ngah

Services at CRC Hospital Selayang

CRC HS conducts Clinical Research & Trials

  • Promote and support industry sponsored and investigator-initiated trials/research (IIR & ISR)
  • Provide Administrative and Facility Support
  • Local Research Registration and Monitoring

Treatment Room

Procedure Room

Entrance Counter

Meeting Room

CRC Hospital Selayang

Clinical Research Centre 
Level 4,
Hospital Selayang,
Lebuhraya Selayang - Kepong,
68100 Batu Caves Selangor

 

Main Phone: +603-61263333 ext 4169

Email: crcselayang@gmail.com 

 

 

ICR
National Institutes of Health (NIH)
Ministry of Health Malaysia
Institute For Clinical Research
Block B4, National Institutes of Health (NIH)
No.1, Jalan Setia Murni U13/52, Seksyen U13
40170 Shah Alam, Selangor Darul Ehsan
Malaysia
 
Phone: 603-3362 7700
Email: contact@crc.gov.my
 

NIH Official Portal

Client 1

Follow us on